US-based biotech startup Soin Neuroscience has tested its spinal cord stimulation system on humans, leveraging very low-frequency stimulation.
The company has commenced the initial testing of its TunedTX platform on humans to assess its safety and tolerance through low-frequency stimulation.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
This spinal cord stimulation system has not yet received approval from the US Food and Drug Administration and is intended for investigational use only.
Soin Neuroscience founder Dr Amol Soin said: “The very low-frequency stimulation platform is one of many novel waveforms across both high and low frequencies that we are testing to help create a versatile experience for our patients while arming our clinicians with the tools they need to help patients achieve maximal pain relief.
“Honestly, right now, we are just testing things in the lab to see what works, what doesn’t work and what is practical to use. Sometimes these experiments blossom into viable programmes and sometimes they are a dead end.”
In January 2020, the company announced that it developed a spinal cord stimulation device for the treatment of chronic pain.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSpinal cord stimulation involves the insertion of electrical leads into the epidural space of the spine, where they deliver electrical stimulation to alleviate a patient’s pain perception.
The company is also developing machine learning and artificial intelligence-based technologies to help physicians’ decision-making on precision medicine.
